Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial

[Display omitted] Switching biologics is now common practice in severe eosinophilic asthma. After insufficient response to anti–IL-5 or 5 receptor (anti–IL-5/5R), the optimal switch between an anti–IL-4R mAb (interclass) or another anti–IL-5/5R drug (intraclass) remains unknown. We sought to compare...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of allergy and clinical immunology Ročník 154; číslo 4; s. 922 - 932
Hlavní autoři:	Bonniaud, Philippe, Beurnier, Antoine, Boudjemaa, Amel, Bourdin, Arnaud, Maurer, C., Beurnier, A., Roux, P., Margelidon, V., Boudjemaa, A., Mangiapan, G., Freymond, N., Russier, M., Dupin, C., Maillard, S. Habib, Khayat, N., Li, X., Leroyer, C., Sattler, C., Guilleminault, L., Gaillot-Drevon, M., Martin, P., Chabrol, A., Pegliasco, H., Sése, L., Tcherakian, C., Ahmed, E., Tummino, C., Mourin, G., Drucbert, M., Keddache, S., Justet, A., Valcke, J., Mercy, M., Jouvenot, M., Godbert, B., Maitre, B., Goyard, C., Cadet, E., Mattei, L., Chauveau, S., Fry, S., Moui, A., Picart, G., Portel, L., Jean, R., Guillo, S., Estellat, C., Prigent, A., Jaffuel, D., Bourayou, Karima, Medina, Hadj Kaci, Djouher, Dahmani, Vacher, Yannick, Allibe, Flora, Barnig, Cindy, Chauveau, Simon, Didi, Toufik, Drucbert, Mélanie, Dupin, Clairelyne, Fouquet, Helen, Fry, Stéphanie, Gaillot-Drevon, Maud, Gamez, Anne Sophie, Garcia, Gilles, Gaspard, Wanda, Gicquello, Alice, Givel, Claire, Guilleminault, Laurent, Habib-Maillard, Stéphanie, Izadifar, Armine, Jouvenot, marie, Jouveshomme, Stéphane, Keddache, Sophia, Khayath, Naji, Leroyer, Christophe, Li, Xing, Magnan, Antoine, Maitre, Bernard, Maurer, Cyril, Michaux, Karine, Moui, Antoine, Oster, Jean-Philippe, Paleiron, Nicolas, Pegliasco, Hervé, Perrin, Julie, Picart, Gaël, Popin-Meyer, Élisabeth, Rami, Hassina, Serra, Mireille Rocca, Rochefort-Morel, Cécile, Romanet, Stéphanie, Rossignoli, Nadine, Russier, Maud, Saint-Raymond, Christel, Sattler, Caroline, Soumagne, Thibaud, Tcherakian, Colas, Tiotiu, Angélica, Vignal, Guillaume, Volpato, Mathilde
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.10.2024 Elsevier
Témata:	Adult Anti-Asthmatic Agents Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal Antibodies, Monoclonal - therapeutic use Asthma Asthma - drug therapy benralizumab dupilumab Female Human health and pathology Humans Interleukin-5 Interleukin-5 - antagonists & inhibitors Interleukin-5 - immunology Life Sciences Male Mepolizumab Middle Aged Randomized Controlled Trials as Topic Receptors, Interleukin-5 Receptors, Interleukin-5 - antagonists & inhibitors severe asthma Treatment Failure Treatment Outcome treatment switch BEC treatment switch OR RAMSES AQLQ Mepolizumab benralizumab SA dupilumab ACT severe asthma CRwNP OCS
ISSN:	0091-6749, 1097-6825, 1097-6825
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	[Display omitted] Switching biologics is now common practice in severe eosinophilic asthma. After insufficient response to anti–IL-5 or 5 receptor (anti–IL-5/5R), the optimal switch between an anti–IL-4R mAb (interclass) or another anti–IL-5/5R drug (intraclass) remains unknown. We sought to compare the effectiveness of these 2 strategies in asthma control in patients with severe eosinophilic asthma and insufficient response to an anti–IL-5/5R mAb. We emulated a target randomized trial using observational data from the Recherche sur les AsthMes SEvèreS (RAMSES) cohort. Eligible patients were switched to an anti–IL-4R mAb or another anti–IL-5/5R drug after insufficient response to an anti–IL-5/5R mAb. The primary outcome was the change in Asthma Control Test score at 6 months. Among the 2046 patients in the cohort, 151 were included in the study: 103 switched to an anti–IL-4R mAb and 48 to another anti–IL-5/5R. At 6 months, the difference in Asthma Control Test score improvement was not statistically significant (mean difference groups, 0.82 [−0.47 to 2.10], P = .213). The interclass group exhibited greater cumulative reduction in oral corticosteroid dose (Pinter-intra, −1.05 g [−1.76 to −0.34], P = .041). The interclass group had a better effect, although not significantly, on reducing exacerbations (Δinter-intra, −0.37 [−0.77 to 0.02], P = .124) and increasing lung function (FEV1) (126.8 mL [−12.7 to 266.4], P = .124). After anti–IL-5/5R mAb insufficient response, switching to dupilumab demonstrated similar improvement in Asthma Control Test scores compared with intraclass switching. However, it appeared more effective in reducing oral corticosteroid use. Larger studies are warranted to confirm these results.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0091-6749 1097-6825 1097-6825
DOI:	10.1016/j.jaci.2024.05.023